- Home
- FEMY vs ENLV Comparison
FEMY vs ENLV Comparison
Compare FEMY & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEMY
- ENLV
- Stock Information
- Founded
- FEMY 2004
- ENLV 2005
- Country
- FEMY United States
- ENLV Israel
- Employees
- FEMY N/A
- ENLV N/A
- Industry
- FEMY Medical/Dental Instruments
- ENLV Biotechnology: Pharmaceutical Preparations
- Sector
- FEMY Health Care
- ENLV Health Care
- Exchange
- FEMY Nasdaq
- ENLV Nasdaq
- Market Cap
- FEMY 25.0M
- ENLV 27.3M
- IPO Year
- FEMY 2021
- ENLV 1995
- Fundamental
- Price
- FEMY $1.14
- ENLV $1.19
- Analyst Decision
- FEMY Strong Buy
- ENLV Strong Buy
- Analyst Count
- FEMY 3
- ENLV 2
- Target Price
- FEMY $10.00
- ENLV $9.50
- AVG Volume (30 Days)
- FEMY 105.5K
- ENLV 102.4K
- Earning Date
- FEMY 11-12-2024
- ENLV 11-29-2024
- Dividend Yield
- FEMY N/A
- ENLV N/A
- EPS Growth
- FEMY N/A
- ENLV N/A
- EPS
- FEMY N/A
- ENLV N/A
- Revenue
- FEMY $1,260,643.00
- ENLV N/A
- Revenue This Year
- FEMY $157.75
- ENLV N/A
- Revenue Next Year
- FEMY $254.07
- ENLV N/A
- P/E Ratio
- FEMY N/A
- ENLV N/A
- Revenue Growth
- FEMY 15.33
- ENLV N/A
- 52 Week Low
- FEMY $0.73
- ENLV $0.81
- 52 Week High
- FEMY $2.40
- ENLV $4.59
- Technical
- Relative Strength Index (RSI)
- FEMY 54.27
- ENLV 50.31
- Support Level
- FEMY $1.05
- ENLV $1.12
- Resistance Level
- FEMY $1.15
- ENLV $1.21
- Average True Range (ATR)
- FEMY 0.07
- ENLV 0.05
- MACD
- FEMY 0.01
- ENLV -0.00
- Stochastic Oscillator
- FEMY 58.82
- ENLV 52.94
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.